Tagresofusp, BPDCN and its management
Naveen Pemmaraju, MD Anderson, USA

Presentation during the South West Acute Leukaemia Forum – 9th February 2022

Registration is free of charge

Satellite Symposium – Sponsored by Novartis

Real World Experience with CAR-T cell therapy
Dr Annalisa Chiappella, IRCCS National Cancer Institute Foundation, Milan

Treatment options in mycosis fungoides and Sézary syndrome – tailoring to your patients
Dr Kevin Molloy, Dublin

Supported by educational grant from Kyowa Kirin

Myeloproliferative neoplasms
Mary Frances McMullin, Belfast

Blast phase MPN
Adam Mead, Oxford

Chronic myeloid leukaemia
Hugues de Lavallade, London

Rare MPN, systemic mastocytosis, eosinophilia and CNL
Deepti Radia, London

Topics:

How does genomics and MRD guide transplant decision making (Dr Rachel Protheroe, Bristol)

Application of genomics in routine clinical practice: cases for roundtable discussion

Panel with cases: Professor David Bowen, Leeds,  Dr Rachel Protheroe, Bristol and Dr Priyanka Mehta, Bristol

Venetoclax – a pragmatic approach – Cases (Dr Mike Dennis, Manchester & Dr Erin Hurst, Newcastle)

Supportive Care Roundtable Workshop:

COVID immunisation strategy for AML patients Dr Justin Loke, Birmingham

Microbiome (Dr David Lowe, London)

High volume v low volume centres (Professor David Bowen, Leeds)

Management of high risk AML – the role of transplant stratification in older fit adults with AML (Professor Guido Kobbe, Düsseldorf)

Debate: Venetoclax-based induction regimens can now be considered as standard of care for the majority of adults over the age of 60 with newly-diagnosed AML

Proposers: Dr Lynn Quek, London & Dr David Taussig, London

Opposer: Dr Sudhir Tauro, Dundee

Topics:

1st line treatments – current recommendations and guidelines (Rebecca Auer, Barts London)

Debate: The role of SCT in the younger patient For: Shirley D’Sa, UCLH,  Against: Roger Owen, Leeds

IgM related disorders – peripheral neuropathy (Prof Michael Lunn, Neurologist, Queen Square, London)

Managing BTKIs and toxicities (Jam Kothari, Oxford)

Mutational analysis – latest thinking in the science (Roger Owen, Leeds)

This day will include lectures and panel discussions from UK and international experts on topics such as keeping services going during COVID, chronic GVHD, dermatology, a ‘difficult cases’ MDT panel

Keeping services going during Covid

James Griffin, Apheresis and ECP audits – reassuring patients

Piers Patten, Covid-19 and Haemato-Oncology – where are we?

Fiona Dignan & Maria Waller, The patient experience during COVID

Chronic GVHD

Francesca Kinsella, UKPS audit data for ECP in chronic GVHD

Harpreet Kaur, Signaling pathways and long term management for chronic GVHD

Nicolaus Kroger, New agents & sequencing treatment for GVHD: when to stop, start, add in or change

Panel discussion

Dermatology review and an MDT review of difficult cases

Dr Arun Alfred, Neurological manifestations of GVHD

Dr Victoria Potter patient including gut GVHD

Registration is free

COVID outcomes and MPN: what do we know
Professor Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, Italy

Genetics and myeloid diagnostics: latest UK guidance
Professor Nick Cross, University of Southampton

Challenges of triple negative thrombocytosis
Dr Rebecca Frewin, Gloucestershire Hospitals

MPNU
Dr Donal McLornan, GSTT & UCLH and Dr Rupen Hargreaves, UCLH

Mastocytosis update
Dr Deepti Radia, Guy’s and St Thomas’ NHS Foundation Trust

CML challenges
Dr Hugues de Lavallade, Guy’s and St Thomas’ NHS Foundation Trust

CMML: how to treat in 2021
Dr Dan Wiseman, The Christie NHS Foundation Trust, Manchester

MDS/AA overlap disorders
Dr Austin Kulasekararaj, King’s College Hospital

Progress with mutCALR vaccine
Professor Morten Holstrom, Herlev University Hospital, Denmark

Interferon for MPN in 2021
Professor Jean Jacques Kiladjian, Hopital St Louis, Paris

Management of accelerated and blast phase MPN
Professor Serge Verstovsek, MD Anderson Cancer Center, Houston

Is disease modification in myelofibrosis an achievable goal?
Professor Adam Mead, University of Oxford

Polycythaemia vera advances and future options
Professor Mary Frances McMullin, Queen’s University Belfast

Current and future landscapes for ET therapy
Dr Anna Godfrey, Cambridge University Hospitals

 Registration is free of charge

The science of CAR-T Dr Elaine Vickers – improving our knowledge Founder of Science Communicated Ltd

Demystifying the patient pathway Genevieve French, CAR-T CNS, King’s College Hospital

UK patient data Dr Andrea Kuhnl, Consultant Haematologist, King’s College Hospital

Palliative care and CAR-T: an integrated approach Maria Mazza-Beange, University Hospitals Bristol

AHP pathways in CAR-T Interviewer: Órla Stewart, Lead Nurse, King’s College Hospital, Aimee Green, Band 7 Physiotherapist CAR-T/Haematology, The Christie, Manchester, Hannah Winn, Senior Specialist Oncology Dietician, The Christie, Manchester

Managing toxicities: case reviews Rose Ellard, Royal Marsden Hospital

Long term follow-up in the CAR-T patient population Órla Stewart, King’s College Hospital

Patient Perspectives: Interview from Manchester Sophie Mulligan, Patient, Rita Angelica, CNS, The Christie, Manchester

Panel discussion: Órla Stewart, Rose Ellard, Sophie Mulligan, Rita Angelica

Addressing the psychological needs of the CAR-T patient Dr Justin Grayer, Consultant Psychologist and
Psychosexual Therapist, Lead for Adult Psychological Support, Royal Marsden Hospital

Patient Perspectives: Interview from Bristol Kenneth Nottage, Patient Maria Mazza-Beange, University Hospitals Bristol

Insights from an Expert Panel: Órla Stewart, Rose Ellard, Maria Mazza-Beange, Andrea Kuhnl

Registration is free of charge

HITT + VITT
Dr Will Lester, Queen Elizabeth Hospital

Laboratory testing for VITT and monitoring of Argatroban and Fondaparinux
Dr Steve Kitchen, Sheffield Haemophilia and Thrombosis Centre

Thrombocytopenic thrombosis – ITP
Dr Gary Benson, Belfast Health and Social Care Trust

Thrombocytopenic thrombosis – TTP & DIC
Dr Jecko Thachil, Manchester Royal Infirmary

An educational resource from Grifols

Registration is free of charge

Clinical update – update from myeloma trials
Dr Charlotte Pawlyn, Institute of Cancer Research, London

Sequential MRD monitoring in myeloma
Dr Ruth de Tute, HMDS, Leeds

Cellular therapies in myeloma
Dr Frances Seymour, Leeds Teaching Hospitals

Panel discussion

Registration is free of charge

Overview and role of bi-specific antibodies
Dr Will Townsend, UCLH, London

Molecular analysis and classification of lymphoid malignancies
Dr Sharon Barrans, Leeds Teaching Hospitals

Molecular subclusters of follicular lymphoma
Professor Reuben Tooze, HMDS & University of Leeds

Panel discussion

Registration is free of charge

Single high-throughput sequencing panel for use in all haematological malignancies: Leeds HMDS experience
Dr Paul Evans, HMDS, Leeds

Eosinophilia – an update
Professor Nick Cross, University of Southampton

Myeloproliferative neoplasms
Dr Adam Mead, Oxford University Hospitals

Registration is free of charge

This meeting was designed to address the challenges and recurring themes faced by the MDT. Sessions are highly interactive with experts reviewing complex cases and sharing latest data on treatments.

Enjoy the following sessions:

Myeloma: Elderly and relapse
Professor Graham Jackson (Newcastle) and Dr Chris Parrish (Leeds)

Chronic Leukaemia: MDM management dilemmas with front line, relapse and ultra-high risk CLL patients
Dr Piers Patten (London), Dr Helen Marr (Newcastle) and Dr Anne Parker (Glasgow)

AML: Newly diagnosed and who to transplant
Dr Mike Dennis (Manchester), Dr Annie Latif (Glasgow) and Dr Rachel Protheroe (Bristol)

Lymphoma Carousel: MCL CAR T when?, bispecifics when? …and some challenging T cell cases
Prof Tim Illidge (Manchester), Dr Wendy Osborne (Newcastle), Dr Tobias Menne (Newcastle) & Dr Piers Patten (London)

ALL: Hot topics everyone should know & how young is young?
Dr Tobias Menne (Newcastle) and Dr Anna Castleton (Manchester)

MDT Panel: When is allograft appropriate – disease specific discussions
Dr Anne Parker (Glasgow), Dr Wendy Osborne (Newcastle), Prof Graham Jackson (Newcastle), Dr Tobias Menne (Newcastle) and Dr Fiona Dignan (Manchester)

Registration Fee: £60 (£50 + VAT)

An educational resource to accompany the ITP Update Day on Friday 14th May

Registration is free of charge

Prevention and management of complications in transplant
Late effects and long-term survivorship
Professor Navneet Majhail, Cleveland Clinic, USA

Registration is free of charge